Angiotech has added one more brick to its stable of end stage renal disease treatment products. The company today got FDA clearance to sell a chronic dialysis catheter it licensed from Rex Medical in April. Known as Hemo-Stream, the catheter is designed to increase flow rates and cut the risk of complications such as embolism and bleeding.
Angiotech previously acquired a related vascular graft business, and it's enrolling for European trials of its Vascular Wrap AV product, a drug-coated device designed to keep permanent dialysis access points open.
- read the release for more info
Related Articles:
Angiotech buys Quill Medical. Report
CombinatoRx gains $7M from extended Angiotech pact. Report